Evidence map›Paper›PMID 41621006›Full record

ArticleJournal of neurology2026

The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study.

Claudia Ledda, Silvia Gallo, Micol Avenali, Carlo Alberto Artusi, Gabriele Imbalzano, Francesca Donetto, Elisa Montanaro, Alberto Romagnolo, Pierfrancesco Mitrotti, Luca Gallo and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Claudia LeddaDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy. claudia.ledda@unito.it.ORCID http://orcid.org/0000-0003-0839-932X
Silvia GalloDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
Micol AvenaliDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Carlo Alberto ArtusiDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
Gabriele ImbalzanoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
Francesca DonettoSC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
Elisa MontanaroSC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
Alberto RomagnoloDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
Pierfrancesco MitrottiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Luca GalloDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Rosa De MiccoDepartment of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Valeria Sant'EliaDepartment of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Mattia SicilianoDepartment of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Alessandro TessitoreDepartment of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Giovanna Calandra-BuonauraIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Giulia GianniniIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Luisa SambatiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Leonardo LopianoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
Enza Maria ValenteIRCCS Mondino Foundation, Pavia, Italy.
Marco BozzaliDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.

Funding

PNRR PNRR-MAD-2022-12376496
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAge at onset is a key determinant of disease course in the general Parkinson's disease (PD) population, but its influence among GBA-PD remains undetermined. This study investigates whether age at onset affects cognitive decline in GBA-PD patients and compares symptoms between GBA-PD and nonGBA-PD groups, stratified by age of onset.

methodsIn this multicentric cross-sectional study, PD patients were stratified into early onset (< 50 years), intermediate onset (50-60 years), and late onset (> 60 years). Demographic-clinical data and scores of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction (SCOPA-AUT), and Beck Depression Inventory (BDI-II) were compared using ANCOVA. The effects of age of onset, GBA1 status, and their interaction were investigated. External validation on cognition was performed using data from the PPMI cohort.

resultsWe analyzed 80 GBA-PD and 236 nonGBA-PD patients. Among GBA-PD, late-onset patients exhibited worse axial scores (p = 0.037), while early-onset had more severe motor complications (p = 0.007) and dysautonomia (p = 0.012). Age of onset and GBA1 status did not influence MoCA scores. Conversely, GBA1 status independently affected MDS-UPDRS parts I and II (p < 0.001 and p = 0.019, respectively) and BDI-II scores (p = 0.002). Analysis on the external dataset (PPMI) showed late-onset PD had lower MoCA scores (p < 0.001) and confirmed GBA1 status did not influence cognition. DISCUSSION: In the first decade of PD, cognitive decline is mainly age and duration dependent, irrespective of GBA1 genotype. Early onset does not increase cognitive risk in GBA-PD, supporting its relevance for counseling and treatment planning.

Indexed as

Cognitive DysfunctionGlucosylceramidaseParkinson DiseaseAgedAge of OnsetCross-Sectional StudiesFemaleHumansMaleMiddle AgedGBA protein, humanGlucosylceramidaseAge at onsetCognitive declineGBA1Non-motor symptomsParkinson’s disease

Identifiers

PMID41621006
PMCPMC12862001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.